Literature DB >> 11845815

High incidence of cervical human papillomavirus infection in women during their first sexual relationship.

Stuart Collins1, Saeideh Mazloomzadeh, Heather Winter, Penny Blomfield, Andrew Bailey, Lawrence S Young, Ciaran B J Woodman.   

Abstract

The prevalence of cervical human papillomavirus increases with increasing numbers of sexual partners, leaving the impression that this infection is acquired only as a result of high risk sexual behaviour. Using longitudinal data from 242 women who had only had one sexual partner, we found that the risk of acquiring cervical human papillomavirus infection was 46% (95% CI 28-64) at three years after first intercourse and that the median time from first intercourse to first detection of human papillomavirus was only three months.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11845815     DOI: 10.1111/j.1471-0528.2002.01053.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  33 in total

Review 1.  Primary prevention of sexually transmitted disease: applying the ABC strategy.

Authors:  S J Genuis; S K Genuis
Journal:  Postgrad Med J       Date:  2005-05       Impact factor: 2.401

2.  Human papillomavirus vaccine for children and adolescents.

Authors: 
Journal:  Paediatr Child Health       Date:  2007-09       Impact factor: 2.253

3.  Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.

Authors:  Ana Cecilia Rodríguez; Alfonso J García-Piñeres; Allan Hildesheim; Rolando Herrero; Matthew Trivett; Marcus Williams; Ivannia Atmella; Margarita Ramírez; Maricela Villegas; Mark Schiffman; Robert Burk; Enrique Freer; José Bonilla; Concepción Bratti; Ligia A Pinto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

4.  Biological and hormonal markers of chlamydia, human papillomavirus, and bacterial vaginosis among adolescents attending genitourinary medicine clinics.

Authors:  L Brabin; E Fairbrother; D Mandal; S A Roberts; S P Higgins; S Chandiok; P Wood; G Barnard; H C Kitchener
Journal:  Sex Transm Infect       Date:  2005-04       Impact factor: 3.519

5.  Prevalence and Determinants of High-risk HPV Infection among 11549 Women from an Opportunistic Screening in Hubei Province.

Authors:  Quan-Fu Ma; Yu-Lin Guo; Han Gao; Bin Yan; Xuan Dai; Meng Xu; Yu-Jing Xiong; Qiu-Zi Peng; Ying Wang; Miao Zou; Xu-Feng Wu
Journal:  Curr Med Sci       Date:  2019-07-25

6.  Epidemiological aspects of genital warts in romania - a 2012 retrospective survey.

Authors:  Carmen Maria Salavastru; Mihaela Cristina Niculescu; Alexandra Zota; Gheorghe Nicola; Horia Silviu Morariu; Caius Solovan; Virgil Patrascu; Georgeta Popovici; Raluca Vladuta; Mihaela Panduru; George-Sorin Tiplica
Journal:  Maedica (Buchar)       Date:  2014-06

7.  Disparities in human papillomavirus vaccine completion among vaccine initiators.

Authors:  Betty Chou; Lauren S Krill; Bernice B Horton; Christopher E Barat; Cornelia L Trimble
Journal:  Obstet Gynecol       Date:  2011-07       Impact factor: 7.661

Review 8.  Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.

Authors:  Paul L McCormack; Elmar A Joura
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

9.  Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay.

Authors:  Jane Steele; Stuart Collins; Kaisheng Wen; Gordon Ryan; Christothea Constandinou-Williams; Ciaran B J Woodman
Journal:  Clin Vaccine Immunol       Date:  2008-07-16

10.  Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trial.

Authors:  Lucia Six; Sepp Leodolter; Heather L Sings; Eliav Barr; Richard Haupt; Elmar A Joura
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.